It is a fixed-dose combination product intended as a continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: Unstable angina or non-ST-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischemia). CoPlavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without a stent). ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, CoPlavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke in medically treated patients eligible for thrombolytic therapy.

headaches or dizziness, Nausea, diarrhea or constipation, indigestion (dyspepsia), stomach ache or abdominal pain, Nosebleeds, increased bleeding (your blood taking longer to clot for example when you cut yourself), or easy bruising.

Bleeding, Intracranial hemorrhage